– Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement including normalization of beta-galactosidase activity in serum and GM1 ganglioside in CSF – Granted Fast Track Designation for both AXO-AAV-GM1 and AXO-AAV-GM2 for the treatment of GM1
- Completed three successful GMP campaigns using suspension-based manufacturing process - All batches achieved target titers and have successfully completed fill and finish - Qualified Person (QP) certification of at least one batch of clinical trial material on-track for Q4 2021 - Obtained
- Designation complements previously granted Rare Pediatric Disease and Orphan Drug designations - Enrollment ongoing in the registration-enabling trial of AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases NEW YORK and DURHAM, N.C. , Nov. 01, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc.
Two new executive positions created in connection with departure of R&D Head NEW YORK and DURHAM, N.C. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with
NEW YORK and DURHAM, N.C. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the U.S.
Consistent dose-dependent improvements across biomarker measures Normalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in six out of seven patients treated across low- and high-dose cohorts Total of ten patients have
Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis NEW YORK , and DURHAM, N.C. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc.
NEW YORK and RESEARCH TRIANGLE PARK, N.C. , Sept. 23, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will
- Study has now enrolled a total of nine patients across low-dose and high-dose cohorts - On track to report 12-month topline safety, biomarker, and efficacy data from Type II low-dose AXO-AAV-GM1 cohort in October 2021 NEW YORK , and DURHAM, N.C. , Sept.
– Completed targeted enrollment of Type II patients in ongoing dose-escalation study of AXO-AAV-GM1 in GM1 gangliosidosis – On track to report 12-month topline safety, biomarker, and clinical outcomes data from low-dose cohort of AXO-AAV-GM1 in late Q3 or early Q4 2021 – Strong cash position
